ArticleDrug delivery and translational research2026
Repurposing felodipine via hyaluronic acid-coated cetylosomes (HCCs) for parenteral active targeting of cancer: Box-Behnken statistical optimization, in vitro characterization, and in vivo studies.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization andJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Felodipine (FEL), an antihypertensive drug, is being repurposed as an anticancer drug. It has low oral bioavailability due to its extensive metabolism in the liver and poor water solubility. This study aimed to develop hyaluronic acid-coated cetylosomes (HCCs) for parenteral delivery of FEL to boost its solubility and anticancer efficacy. FEL-HCCs were prepared by the thin-film hydration technique based on Box-Behnken design. Amounts of cetyl alcohol, Brij 97, and hyaluronic acid were the independent factors. The optimized HCC (OHCC) formula which showed the highest desirability value (0.626), was composed of 100 mg Brij 97, 32.44 mg CA, and 10 mg HA. It showed the minimum vesicle size (156.72 nm) and polydispersity index (0.134), and the maximum entrapment efficiency% (72.04%) and zeta potential (-30.58 mV). After lyophilization and sterilization of the OHCC formula, it showed a 2.01-fold enhancement in FEL release compared to the market tablet, with no significant difference in release before and after lyophilization or sterilization. The sterilized OHCC was stable for six months. The OHCC showed an enhanced cytotoxicity against MCF-7 cells with 6.61-fold compared to pure FEL powder. Additionally, the OHCC potentiated the antiproliferative effect of doxorubicin, as evidenced by a raised Bax/Bcl-2 ratio and caspase 9 content, and suppressed VEGF levels. In vivo, the OHCC markedly reduced tumor growth, particularly in combination with doxorubicin. The histopathological investigation supported the apoptotic and necrotic death of cancer cells. These findings suggest that HCCs represent a promising nanocarrier system for the targeted parenteral delivery of FEL in cancer therapy.
Indexed as
Identifiers
41941056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.